Prognostic and predictive value of baseline PSMA-PET total tumour volume and SUVmean in metastatic castration-resistant prostate cancer in ENZA-p (ANZUP1901): a substudy from a multicentre, open-label, randomised, phase 2 trial

Journal:
The Lancet Oncology
Published:
DOI:
10.1016/s1470-2045(25)00339-0
Affiliations:
31
Authors:
42
Go to article
Institutions Authors Share
The University of Sydney (USYD), Australia
3.333333
 0.15
Garvan Institute of Medical Research, Australia
2.333333
 0.11
University of New South Wales (UNSW Sydney), Australia
1.833333
 0.08
Royal Adelaide Hospital (RAH), Australia
1.500000
 0.07
The University of Melbourne (UniMelb), Australia
1.500000
 0.07
The University of Queensland (UQ), Australia
1.166667
 0.05
The University of Western Australia (UWA), Australia
1.166667
 0.05
St Vincent's Hospital Sydney, Australia
1.166667
 0.05
Royal Brisbane and Women's Hospital (RBWH), Australia
1.000000
 0.05
La Trobe University, Australia
0.833333
 0.04
Sir Charles Gairdner Hospital (SCGH), Australia
0.833333
 0.04
The Kinghorn Cancer Centre (TKCC), Australia
0.666667
 0.03
Bankstown-Lidcombe Hospital, Australia
0.500000
 0.02
Queensland University of Technology (QUT), Australia
0.500000
 0.02
Chris O'Brien Lifehouse, Australia
0.500000
 0.02
Peter MacCallum Cancer Centre (Peter Mac), Australia
0.500000
 0.02
Olivia Newton-John Cancer Wellness and Research Centre, Australia
0.500000
 0.02
The University of Adelaide (Adelaide Uni), Australia
0.500000
 0.02
Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP), Australia
0.333333
 0.02
Monash University, Australia
0.333333
 0.02
Olivia Newton-John Cancer Research Institute (ONJCRI), Australia
0.333333
 0.02
Austin Health, Australia
0.333333
 0.02
Eastern Health, Australia
0.333333
 0.02
Interested in Biomedical Engineering?